Outlook Therapeutics Inc (NASDAQ:OTLK) does about 557.52K shares in volume on a normal day but saw 1180917 shares change hands in Monday’s trading. The company now has a market cap of 133.48M USD. Its current market price is $10.26, marking a decrease of -14.07% compared to the previous close of $11.94. The 52 week high reached by this stock is $40.60 whilst the lowest price level in 52 weeks is $4.00.
Outlook Therapeutics Inc (OTLK) has a 20-day trading average at $8.11 and the current price is -74.73% off the 52-week high compared with 156.24% distance from its 52-week low. The 50-day simple moving average of the closing price is $8.24 and its 200-day simple moving average is $14.20. If we look at the stock’s price movements over the week, volatility stands at 22.31%, which decreases to 19.45% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 59.10 to suggest the stock is neutral.
The consensus objective for the share price is $39.86, suggesting that the stock has a potential upside of 74.26% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 27, 2024 when BTIG Research upgraded the stock to “Buy” and issued a price target of $50. Chardan Capital Markets also upgraded the stock to “Buy” from Neutral on February 15, 2024 at a price target of $3.
Outlook Therapeutics Inc (OTLK) stock is up 18.89% over the week and 17.45% over the past month. Its price is 30.20% year-to-date and -51.14% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of -$0.8 above consensus estimates by $0.2. OTLK’s earnings per share are forecast to grow by 29.40% this year and 40.40% over next year.
To reach the target analysts have set, the stock logically needs to grow 74.26 percent from here.
Outstanding shares total 13.01M with insiders holding 36.81% of the shares and institutional holders owning 6.88% of the company’s common stock. The company has a return on equity of -827.71%. The beta has a value of 0.04.
